- Home
- GERN vs SABR Comparison
GERN vs SABR Comparison
Compare GERN & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | SABR |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 811.2M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GERN | SABR |
|---|---|---|
| Price | $1.10 | $1.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $4.25 | $2.11 |
| AVG Volume (30 Days) | 5.9M | ★ 6.5M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.85 | ★ 283.56 |
| EPS | ★ N/A | N/A |
| Revenue | $1,065,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | $28.49 | $4.34 |
| Revenue Next Year | $44.73 | $4.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $1.04 | $0.81 |
| 52 Week High | $2.01 | $2.50 |
Technical Indicators
Market Signals| Indicator | GERN | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 21.49 |
| Support Level | $1.08 | $1.49 |
| Resistance Level | $1.26 | $1.61 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 8.33 | 4.04 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.